Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance On-Demand Webinar Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…Danielle Pillsbury2025 年 5 月 23 日
CERTAINTY 2025: The power of Model-Informed Drug Development Blog CERTAINTY 2025: 模型引导的药物开发的强大力量 We cover the key takeaways from CERTAINTY 2024, including the power of Model-Informed Drug Development…Certara2025 年 5 月 16 日
Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk Webinar 探索先行:分阶段 QTc 研究策略如何减少时间、成本及监管风险 2025 年 7 月 24 日 - 11am ETDanielle Pillsbury2025 年 5 月 5 日
Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies Fact Sheet Non-Animal Navigator™: 专家策略与 AI 生物模拟减少、优化或替代动物实验 Certara Non-Animal Navigator™ 解决方案通过以下方式助力企业转型:Danielle Pillsbury2025 年 4 月 30 日
Certara Announces Second Annual Certainty U.S. Event Announcement Certara 举办 Second Annual Certainty U.S. 活动 Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…Certara2025 年 4 月 22 日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions Webinar Adagrasib 药物相互作用的临床与基于生理的药代动力学模型评估 2025 年 6 月 17 日 - 美国东部时间上午 11:00Danielle Pillsbury2025 年 4 月 21 日
In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD) Blog 不容错过:CHI 与 Certara 关于人工智能(AI)赋能模型引导的药物开发(MIDD)网络研讨会 2025 年 4 月 18 日 What’s next for drug development? Recapping our MIDD in the age of…Certara2025 年 4 月 18 日
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing Press Release Certara 推出 Non-Animal Navigator™ 解决方案,助力药物开发者减少对动物试验的依赖 New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…Simona Colucci2025 年 4 月 14 日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究(IMPAACT 2017/MOCHA):一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究 The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025 年 3 月 20 日
MIDD in Japan – Implementations, challenges and opportunities Publication MIDD in Japan – Implementations, challenges and opportunities In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…Danielle Pillsbury2025 年 3 月 12 日